Breaking Research News from sources other than Breastcancer.org
Comments
-
You're welcome, BevJen!
thisiknow, the actual study being referenced seems to be here: https://www.nature.com/articles/s41467-019-14065-6
It only seems to be comparing sevoflurane and propofol. It goes into a lot of detail, but...
"In summary, in this report we show that a volatile anesthetic sevoflurane leads to more lung metastasis than an intravenous anesthetic propofol following surgery in two mouse models of spontaneous metastasis."
0 -
one quick question on that study does this mean lumpectomies: "after breast tumor resecting surgery" and so then they didn't look at masectomies.
One of my goals this week is to call my Nurse Navigator b/c she is involved w/the cancer related stuff at the hospital (like support groups, etc) and ask her about a how to read medical studies and news class at the hospital. :-)
0 -
2019whatayear, the study used mouse models... they were resecting tumors in mice! The results might not apply in humans at all (but gives researchers some reason to think it might).
Apparently, the potential effect of anesthesia on long-term outcomes is an active area of research.
Here is a retrospective study done on bc patients a year ago which found no difference in long term outcomes between IV and inhaled anesthesia: https://anesthesiology.pubs.asahq.org/article.aspx?articleid=2712483 But *this* study refers to a previous study from 2016 (https://ekja.org/journal/view.php?doi=10.4097/kjae.2016.69.2.126) that did seem to show a difference between sevoflurane and propofol, but notes that the previous study's sample size was small.
Sorry the results aren't clear yet.
0 -
Naltrexone for BC? Links to a clinical trial as well as a study in dogs below. Targets estrogen . Have not found mention of positive/negative interaction with other drugs. A friend mentioned that her partner will be using it for early onset alzheimer/dementia. Studies into BC treatment seem to be just starting. The main use so far seems to be for alcohol and opiod addiction.
https://clinicaltrials.gov/ct2/show/NCT00379197
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171873/
0 -
psychedelics....... interesting. Suggested reading, Michel Pollan "How to Change Your Mind" https://bioneers.org/how-to-change-your-mind-a-review-of-michael-pollans-latest-book-about-psychedelics-zmbz1805/ . These were being researched fairly intensively until tune in, tune out ,drop out, became the rage. Lots of interesting information in Pollan's book. Research seems to be starting up again .
0 -
If one acid trip can stop years of cancer anxiety- sign me up! Debbew re: the anesthetic study thanks for the clarification- I guess it is what it is since I already had surgery.
0 -
I wouldn't count on LSD to reduce anxiety. It might for some but it could go in the complete opposite direction for others. There are just too many variables to take into consideration.
I would suggest seeing what you can find out about using low-dose psilocybin for cancer patients
0 -
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
0 -
Hi, I have joined this forum in the hope of sharing our experience...and your post seemed to be one of the only ones that references the circumstances surrounding my mother's passing...My name is Robyn, I reside in Australia. This post is difficult to write, however my sister and I feel it would have been valuable information to us if we had it late last year. Our gorgeous mother was diagnosed with Stage IV mets that had spread to her bones, Aug 2019. Completely out of the blue. We were advised that once the initial rounds of radio were complete a regime of Kisqali/Ribociclib would enable a diagnosis of 10 years. Only 10 weeks later mum was transferred from rehab to emergency then ICU with sudden onset of lung inflammation in both lungs. After 12 days, we had to make the devastating decision to turn of life support. 4 days later, whilst researching Kisqali/Ribociclib we happened upon an FDA warning directly identifying sudden lung inflammation as a side effect of this drug, and as such patients should have their lungs monitored. Our mother began Kisqali/Ribociclib on Sept 19 2019, 3 days after her 70th birthday. This FDA warning was released on September 13 2019. Our mother was an otherwise healthy woman, with a rich and loving life ahead, she did everything she could in ICU to give herself a chance, "i want to get better" was her anthem between oxygen masks. Eventually mum was intubated whilst her ICU and Infectious disease specialists tested for all possible types of infection/diseases/pneumonia possible. We have lodged documents with Novartis and they are requesting follow up. In no way do we want to deter women from this treatment, we were so happy mum had this option, Kisqali/Ribociclib would have let her and her children and grandchildren say hello each day and goodbye on our own terms if we had the chance. We only think it should be a safe playing ground and so have decided to share this information. we also believe it should be a fare playing ground and are at a loss as to why these alerts are not sent out globally, given they are used globally. We are heart broken, we are completely devastated as she was everything to us. Nothing can be done to bring mum back but we so do not wish upon anyone else. Just ask the question, is all.
0 -
Robyn and sister, My condolences the loss of your mother and thank you for sharing.
0 -
Yes--Robyn and sister thank you for sharing that with this group and my deepest sympathies on the loss of your mother.
0 -
By combining Herceptin and Tykerb treatments in 66 women with HER2-positive breast cancer before surgery and comparing the results to 191 similar women who were either treated with just one of the drugs or neither of them, 7 of the 66 women showed no trace of their tumors afterward. Another 11 of them showed considerable shrinkage of their tumors.
0 -
Not breast cancer, but this was posted recently on a Facebook cancer group I am in. It was interesting the negative effect of hyaluronic acid on myeloma. . . as hyaluronic acid is in many, many cosmetics. . . for it's plumping effect. . even cosmetic brands considered a bit "healthier" like Aveda use it. . .
0 -
RobynKH , deepest sympthies for the loss of your mother. The more we share, the more learned
0 -
How some states are taking unusual action to lower prescription drug prices
0 -
In terms of state laws, a new law in PA requires insurance companies to cover approved cancer drugs prescribed for metastatic patients (rather than forcing a "fail first" with cheaper drugs):
(notes that "Legislatures in Georgia, Illinois, and Maryland have passed similar legislation in recent years.")
0 -
Robots steady breast cancer surgeon's hands in first human trial
Writing in Nature Communications, researchers in Maastricht and at Eindhoven University of Technology describe a pilot trial in which a specialist surgeon used the robot to re-route lymphatic vessels around women's scar tissue. The surgeon operated on 20 women and used the robot in eight of those procedures.
0 -
debbew: thanks for all your interesting posts!
lumpie: we are thinking of you & sending you well wishes
0 -
Bell Ringing Not So Joyous for Cancer Patients?
Greater treatment-related distress for those who rang bell at end of treatment
0 -
Really interesting about the bell. Since I don't care for the image of cancer as a "battle" or a "war", I was less than pleased with a "conquering hero" victory celebration. I did the necessary treatment. A quiet glass of wine would have been nice.
0 -
Not a breast cancer cure, but who knows what this sort of treatment may contribute to management of side effects etc......
Breakthrough trials explore the link between immune cells in our gut and brain... So could a matchbox-sized electrical implant end the misery of diabetes, asthma AND arthritis?
0 -
yw, santa, glad you found them interesting!
I'll add my thanks to marijen and mystical and all the others who post and comment, but especially Lumpie for starting and really running this thread (hope things are going well!).
0 -
Cancer and Metabolic Disorders Linked with Testosterone Levels in Both Sexes, but with Differences
Additionally, they found that genetically higher testosterone levels increased the risks of breast and endometrial cancers in women, and of prostate cancer in men. "MR analyses indicated that testosterone increases prostate cancer risk in men … We found evidence that testosterone increased the risk of estrogen receptor (ER)-positive but not ER-negative breast cancer … There was also evidence for a protective effect of SHBG [sex-hormone binding globulin] on risk of endometrial cancer in women, which was consistent across all models, but a risk-increasing effect of SHBG on ER [estrogen receptor]-negative breast cancer."
0 -
I just don’t understand why it took them so long to figure out the testosterone thing. It’s included with the HRT treatment for menopause. At least what I was given.
0 -
My TNBC was 90% AR+....
0 -
Dark Chocolate Intake Acutely Enhances Neutrophil Count in Peripheral Venous Blood
Beside the well-established impact on decreasing the risk of cardiovascular diseases (1), recent attention has been paid to the relationship between cocoa-containing foods and the immune system (2), showing that dark chocolate consumption enhances the systemic defense against bacterial (3) and viral (4) infections. Hence, the current study aimed at investigating the acute effect of dark chocolate intake on peripheral blood leukocytes.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC58353...
Iran J Pathol. 2017 Summer; 12(3): 311–312.
PMCID: PMC5835384
PMID: 29531561
{Any excused for chocolate!}
0 -
Add-On Keytruda Doubles pCR Rate in Early Breast Cancer
Rate of complete response reached 60% in triple-negative cohort
Escalating preoperative systemic therapy with immunotherapy improved pathologic complete response (pCR) rates for women with high-risk early breast cancer, results of a phase II trial showed.
Among 240 women with stage II/III breast cancer and HER2-negative disease, those assigned to neoadjuvant chemotherapy plus pembrolizumab (Keytruda) achieved a pCR rate of 44%, as compared with 17% for a control group on chemotherapy alone, reported Rita Nanda, MD, of the University of Chicago, and colleagues.
Patients with triple-negative disease in the so-called I-SPY2 trial had pCR rates of 60% with pembrolizumab, a PD-1-directed checkpoint inhibitor, and 22% without it. While those with hormone receptor (HR)-positive/HER2-negative disease had rates of 30% versus 13%, respectively, as described in JAMA Oncology.
0 -
Q & A: How Corrupt Scientists Threaten Public Health
David Michaels, a GW professor and former Obama administration official, talks about his new book and how manufactured studies harm consumers.
https://gwtoday.gwu.edu/q-how-corrupt-scientists-t...
{This is more about public health than cancer specifically, but it is interesting - and troubling in an environment in which many are uncertain about what science to trust.}
0
